Denali Therapeutics Inc. Increase (Decrease) in Contract with Customer, Liability
Denali Therapeutics Inc. (DNLI) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2025-02-27
- Denali Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-12-31 was $0.00.
- Denali Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-09-30 was $0.00.
- Denali Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-06-30 was $0.00.
- Denali Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-03-31 was $0.00.
- Denali Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was $0.00.
- Denali Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was $0.00.
- Denali Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$31.31M.
- Denali Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was -$11.93M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | -$23.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | -$23.00K derived: sum of 3 quarters · filed 2025-02-27 | -$3.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-08 | -$23.00K derived: sum of 2 quarters · filed 2025-02-27 | -$3.40M derived: sum of 3 quarters · filed 2025-02-27 | -$3.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$3.40M derived: sum of 2 quarters · filed 2025-02-27 | -$3.40M derived: sum of 3 quarters · filed 2025-02-27 | -$31.31M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$3.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$3.38M derived: sum of 2 quarters · filed 2023-11-07 | -$31.29M 10-Q · filed 2023-11-07 | -$32.61M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$27.91M 10-Q · filed 2023-08-08 | -$29.24M derived: sum of 3 quarters · filed 2024-02-28 | -$33.66M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$27.91M 10-Q · filed 2023-05-08 | -$29.24M derived: sum of 2 quarters · filed 2024-02-28 | -$33.66M derived: sum of 3 quarters · filed 2024-02-28 | -$40.81M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$5.75M derived: sum of 2 quarters · filed 2024-02-28 | -$12.89M derived: sum of 3 quarters · filed 2024-02-28 | -$11.93M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$4.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$11.57M derived: sum of 2 quarters · filed 2022-11-03 | -$10.60M 10-Q · filed 2022-11-03 | -$11.93M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$7.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$6.17M 10-Q · filed 2022-08-08 | -$7.51M derived: sum of 3 quarters · filed 2023-02-27 | -$16.78M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $969.00K 10-Q · filed 2022-05-05 | -$364.00K derived: sum of 2 quarters · filed 2023-02-27 | -$9.64M derived: sum of 3 quarters · filed 2023-02-27 | -$15.21M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$10.61M derived: sum of 2 quarters · filed 2023-02-27 | -$16.18M derived: sum of 3 quarters · filed 2023-02-27 | -$19.25M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$9.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$14.85M derived: sum of 2 quarters · filed 2021-11-04 | -$17.92M 10-Q · filed 2021-11-04 | -$21.41M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$5.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$8.64M 10-Q · filed 2021-08-04 | -$12.13M derived: sum of 3 quarters · filed 2022-02-28 | -$13.31M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$3.07M 10-Q · filed 2021-05-05 | -$6.56M derived: sum of 2 quarters · filed 2022-02-28 | -$7.74M derived: sum of 3 quarters · filed 2022-02-28 | -$8.58M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$3.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$4.67M derived: sum of 2 quarters · filed 2022-02-28 | -$5.51M derived: sum of 3 quarters · filed 2022-02-28 | -$6.29M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$2.02M derived: sum of 2 quarters · filed 2020-11-05 | -$2.80M 10-Q · filed 2020-11-05 | $8.87M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$839.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$1.62M 10-Q · filed 2020-08-07 | $10.05M derived: sum of 3 quarters · filed 2021-02-26 | $8.86M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$777.00K 10-Q · filed 2020-05-07 | $10.89M derived: sum of 2 quarters · filed 2021-02-26 | $9.70M derived: sum of 3 quarters · filed 2021-02-26 | $8.05M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $11.67M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $10.47M derived: sum of 2 quarters · filed 2021-02-26 | $8.82M derived: sum of 3 quarters · filed 2021-02-26 | $68.78M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$2.84M derived: sum of 2 quarters · filed 2019-11-06 | $57.11M 10-Q · filed 2019-11-06 | $57.11M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $58.30M 10-Q · filed 2019-08-06 | $58.30M derived: sum of 3 quarters · filed 2020-02-27 | $58.30M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $59.95M 10-Q · filed 2019-05-08 | $59.95M derived: sum of 2 quarters · filed 2020-02-27 | $59.95M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 10-K · filed 2020-02-27 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |